You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Dr Reddys rises after launching sapropterin dihydrochloride powder in US

Capital Market 

Dr. Reddy's Laboratories gained 2.2% to Rs 4719 after the drug major announced the launch of a generic version of sapropterin dihydrochloride powder for oral solution, 100 mg in the US market.

Dr. Reddy's Laboratories announced the launch of sapropterin dihydrochloride powder for oral solution, 100 mg, a therapeutic equivalent generic version of Kuvan powder approved by the U.S. Food and Drug Administration (USFDA).

Sapropterin dihydrochloride is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU).

We are pleased to launch this generic version of sapropterin dihydrochloride powder for Oral Solution, illustrating our continued commitment to bring affordable generic medicines to market for patients, says Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy's Laboratories. "At the same time, this product demonstrates that we are actively expanding the breadthof our portfolio with a treatment for a rare disease."

Dr Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses - pharmaceutical services & active ingredients, global generics and proprietary Products. It reported a consolidated net profit of Rs 27.90 crore in Q3 FY21 as compared to net loss of Rs 538.40 crore in Q3 FY20. Net sales during the quarter rose 12.5% YoY to Rs 4,929.60 crore.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, April 07 2021. 13:16 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU